Table 2 Attitudes toward clinical trials and study participation

Persons diagnosed with PD should be asked to participate in CTs

559

83

81

12

32

5

If patients refuse to participate in CTs, new treatments will not become available

417

63

140

21

108

16

Research results should be discussed with research participants

634

95

17

3

13

2

I think it is important that all clinical trials’ results be published and health-care professionals gain access to them

620

93

29

4

19

3

I would like to receive as much information as possible about the trial and the new drug before I make a decision about participation in a CT

561

83

57

9

54

8

New PD medications are usually studied in comparative trials (an old drug is compared to a new substance or a placebo); I would like to participate in this kind of CT

336

50

177

26

157

23

I would participate in clinical trials because it would enable me to help other patients with Parkinson’s disease

567

86

64

10

32

5

I would participate in a CT in which there is a possibility of receiving a placebo (placebos do not contain any active ingredient)

274

42

145

22

238

36

I would participate in a CT if it involved a significant risk of severe adverse effects (adverse effects that could lead to prolongation of hospitalization or cause permanent disability)

34

10

100

15

492

75